Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 103 of 110 Updated Nov 17, 2026

Tesamorelin + Ipamorelin

Tesa+Ipa · long-acting GHRH + selective GHRP blend

FDA-APPROVED (COMPONENT) · FDA-APPROVED GHRH ANALOG (TESAMORELIN) + SELECTIVE GHRP (IPAMORELIN) BLEND

Mechanism of action

Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.

Researched effects

Visceral adiposity reduction (Tesamorelin signal); improved sleep and recovery; cleaner side-effect profile than CJC-DAC blends; favoured for HIV-lipodystrophy-adjacent body composition goals

Dosing reported in literature

1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off

Known concerns

Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)

Continue reading